NBP — NovaBridge Biosciences Share Price
Last trade - 00:00- $158.92m
- -$31.93m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.79 | ||
| Price to Tang. Book | 0.79 | ||
| Price to Free Cashflow | 51.19 | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -59.64% | ||
| Return on Equity | -37.95% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 13.65 | -1.55 | 0.63 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its segments include oncology and ophthalmology. The oncology segment focuses on the research and development of precision immuno-oncology agents for the treatment of cancer. The ophthalmology segment focuses on research and development of ophthalmologic indications such as wet age-related macular degeneration (Wet AMD) and diabetic macular edema (DME). Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. VIS-101 targets VEGF-A and ANG-2 to provide more potent treatment benefits for patients with wet AMD and DME.
Directors
- Jingwu Zhang Zang CHM (65)
- Zheru Zhang PRE (58)
- Joan Shen CEO (59)
- John Long CFO
- Weimin Tang EVP (55)
- Yunhan Lin VPR (43)
- Neil Warma GMG (58)
- Gigi Qi Feng OTH (39)
- Cheng Li OTH (37)
- Ivan Yifei Zhu OTH (52)
- Jielun Zhu OTH (45)
- Wei Fu DRC (39)
- Mengjiao Jiang DRC (41)
- Jie Yu DRC (46)
- Bing Yuan DRC (52)
- Chun Kwok Alan Au IND (48)
- Pamela Klein IND (59)
- Conor Chia-hung Yang IND (58)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 30th, 2016
- Public Since
- January 17th, 2020
- No. of Employees
- 30
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 266,798,199
- Address
- Suite 400, 2440 Research Blvd, ROCKVILLE, 20850
- Web
- https://www.novabridge.com/
- Phone
- +1 3016702800
- Auditors
- PricewaterhouseCoopers LLP
Latest News for NBP
Upcoming Events for NBP
Full Year 2026 NovaBridge Biosciences Earnings Release
Similar to NBP
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
As of Today at 22:24 UTC, shares in NovaBridge Biosciences are trading at $1.37. This share price information is delayed by 15 minutes.
Shares in NovaBridge Biosciences last closed at $1.37 and the price had moved by -68.79% over the past 365 days. In terms of relative price strength the NovaBridge Biosciences share price has underperformed the S&P500 Index by -72.2% over the past year.
The overall consensus recommendation for NovaBridge Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNovaBridge Biosciences does not currently pay a dividend.
NovaBridge Biosciences does not currently pay a dividend.
NovaBridge Biosciences does not currently pay a dividend.
To buy shares in NovaBridge Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.37, shares in NovaBridge Biosciences had a market capitalisation of $158.92m.
Here are the trading details for NovaBridge Biosciences:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: NBP
Based on an overall assessment of its quality, value and momentum NovaBridge Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in NovaBridge Biosciences is $8.50. That is 520.44% above the last closing price of $1.37.
Analysts covering NovaBridge Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.30 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NovaBridge Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -47.38%.
As of the last closing price of $1.37, shares in NovaBridge Biosciences were trading -39.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The NovaBridge Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
NovaBridge Biosciences' management team is headed by:
- Jingwu Zhang Zang - CHM
- Zheru Zhang - PRE
- Joan Shen - CEO
- John Long - CFO
- Weimin Tang - EVP
- Yunhan Lin - VPR
- Neil Warma - GMG
- Gigi Qi Feng - OTH
- Cheng Li - OTH
- Ivan Yifei Zhu - OTH
- Jielun Zhu - OTH
- Wei Fu - DRC
- Mengjiao Jiang - DRC
- Jie Yu - DRC
- Bing Yuan - DRC
- Chun Kwok Alan Au - IND
- Pamela Klein - IND
- Conor Chia-hung Yang - IND